Other MMA Content
Contacts
Stay Updated
subscribeThe U.S. Drug Enforcement Administration has announced plans to reduce the amount of opioids that can be manufactured by drug makers in a given year to further combat the opioid epidemic.
This is consistent with President Trump’s “Safe Prescribing Plan” that seeks to “cut nationwide opioid prescription fills by one-third within three years.” The new proposal decreases manufacturing quotas for the six most frequently misused opioids during 2019 by an average of 10 percent, compared to 2018.
This would help reduce the amount of drugs potentially diverted for trafficking and used to facilitate addiction. Under the proposed new rule, if the DEA believes a company’s opioids are being diverted for misuse, they will reduce the amount of opioids that company can make.
The new regulatory plan comes after West Virginia sued the DEA over its drug quota rules, arguing the agency’s policy wrongfully sets manufacturing quotas based on the amounts of pills that drug makers expect to sell, not on legitimate medical needs.
The state has argued that this approach has contributed to increasing the addiction problem and the illegal diversion of pain medication, while bowing to the interests of the drug industry.
The new DEA proposal calls for the government to take into account input from important stakeholders, including states and the components of the U.S. Department of Health and Human Services, such as the Food and Drug Administration, the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services, when setting quotas.
The unveiling of the proposal on last Tuesday comes after federal, state and local law enforcement officials in West Virginia announced a crackdown on an opioid trafficking ring in Huntington, an area known as “ground zero” for the epidemic.
West Virginia has been among the hardest-hit states by the country’s opioid crisis.
According to the CDC, 42,000 people died nationwide from opioid overdoses in 2016, the last year with publicly available data.
The DEA has proposed to reduce more commonly prescribed schedule II opioids, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, and fentanyl.
Ultimately, revised limits will encourage vigilance on the part of opioid manufacturers, help DEA respond to the changing drug threat environment, and protect the American people from potential addictive drugs while ensuring that the country has enough opioids for legitimate medical, scientific, research, and industrial needs.
Once the aggregate quota is set, DEA allocates individual manufacturing and procurement quotas to those manufacturers that apply for them. DEA may revise a company’s quota at any time during the year if change is warranted due to increased or decreased sales or exports, new manufacturers entering the market, new product development, or product recalls.
In 2016, the Centers for Disease Control and Prevention issued guidelines to practitioners recommending a reduction in the prescribing of opioid medications for chronic pain. DEA and its federal partners have increased efforts in the last several years to educate practitioners, pharmacists, manufacturers, distributors, and the public about the dangers associated with the misuse of opioid medications and the importance of proper prescribing. Controlling the supply of opioids is a potentially important addition to the government’s ability to help control the opioid epidemic.
If you have questions about how the new regulations could affect your health care plan, your employees, and your organization, contact your Marsh & McLennan representative.
Related Offerings
Employee Health & BenefitsYou May Also Be Interested In
- Event
06.21.2018
Webinar | 2018 Mid-Year Compliance Update
- Blog
10.13.2017
Telemedicine and HSAs
- Blog
12.27.2017
Employee Benefits in 2018
- Blog
01.22.2019
Live Well Work Well Newsletters
- Blog
05.24.2018
IRS Releases 2019 HSA Contribution Limits and HDHP Deductible and Out-of-Pocket Limits
- Blog
05.30.2018
The Opioid Crisis: A Serious Societal and Business Issue
- Event
08.16.2018
Webinar | Surviving a DOL Audit
- Event
10.18.2018
Webinar | Annual Required Notices
- Event
11.20.2018
Webinar | Back to Basics: Consumer-Based Plans 101
- Event
12.20.2018
Webinar | 2018 Year in Review & Future Benefits Forecast
- Event
10.12.2018
Webinar | Q3 2018 Health Care Reform Update
- Event
12.14.2018
Webinar | Q4 2018 Health Care Reform Update
- Blog
06.13.2018
IRS Issues Affordability Percentage Adjustment for 2019
- Event
09.18.2018
The Opioid Epidemic: A Public Health Crisis
- Event
07.12.2018
Webinar | Self-Insurance
- Event
09.13.2018
Webinar | Medicare Issues for Employers
- Blog
06.20.2018
U.S. DOL Releases Final Rule Expanding Association Health Plans
- Event
07.24.2018
Health Insurance Tactics for Tomorrow's Benefits Package
- Event
03.14.2017
The Future of Health Care & Employee Benefits
- Blog
07.25.2018
Is An EAP Worth The Investment?
- Blog
08.06.2018
The Opioid Crisis: Using Alternative Approaches to Manage Pain
- Blog
08.07.2018
Open Enrollment: The Benefits of Smarter Communications
- Blog
08.17.2018
Open Enrollment: Ways to Control Costs
- Blog
08.21.2018
Tobacco: Still Affecting Businesses’ Financial Health
- Event
09.06.2018
Webinar | Association Health Plans
- Blog
06.29.2018
The DOL's New Association Health Plan Rules and What They Actually Mean
- Blog
09.06.2018
Rule #1 For Effective Open Enrollment: Start Early
- Blog
09.10.2018
Compliance Update: Medicare Part D Notice Reminder
- Blog
09.11.2018
2018 Stop-Loss Survey
- Blog
09.12.2018
Compliance Update: Medical Loss Ratio Rebates Under the Affordable Care Act
- Blog
09.17.2018
Is Marijuana the Answer to the Opioid Addiction Problem?
- Event
10.11.2018
Webinar | Cafeteria Plans
- Event
11.08.2018
Webinar | Consumer-Based Plans
- Event
12.13.2018
Webinar | 2019 Compliance Preview
- Blog
10.09.2018
IRS Releases Final 2018 ACA Reporting Forms and Instructions
- Blog
11.02.2018
Compliance Update: HRAs Poised For a Facelift
- Blog
11.02.2018
Build a Positive Workplace Culture That Promotes Honest Communication
- Blog
11.08.2018
Four Steps Employers Can Take to Help Alleviate the Opioid Crisis
- Blog
11.29.2018
IRS Increase Health FSA Contribution Limit for 2019 & Adjusts Other Benefit Limits
- News
11.29.2018
Article Published: Engaging Your Employees Requires Your Own Engagement
- Event
01.29.2019
Employment Law Landscape 2019
- Blog
12.03.2018
Employment Law Update: Minimum Wage Keeps Climbing
- Blog
12.12.2018
Can Telemedicine Make Health Care Benefits Healthier?
- Event
07.18.2019
Webinar | MMA U: Annual Required Notices
- Event
01.17.2019
Webinar | MMA U: ACA Reporting Requirements
- Event
08.15.2019
Webinar | MMA U: Association Health Plans
- Event
02.21.2019
Webinar | MMA U: FMLA & Employee Benefits
- Event
03.21.2019
Webinar | MMA U: Federal Continuation Coverage
- Event
09.19.2019
Webinar | MMA U: New HRA Options
- Event
10.17.2019
Webinar | MMA U: Health Savings Accounts
- Event
11.21.2019
Webinar | MMA U: ACA Reporting Requirements Part 2
- Event
04.18.2019
Webinar | MMA U: HIPAA Privacy & Security Training
- Event
05.16.2019
Webinar | MMA U: Wellness Programs
- Event
06.20.2019
Webinar | MMA U: Mid-Year Compliance Review
- Event
12.19.2019
Webinar | MMA U: Year End Checklist/Future Forecast
- Event
02.28.2019
Seminar | Understanding Mental Health in the Workplace
- Event
04.25.2019
Webinar | Total Worker Health
- Blog
12.20.2018
Making a List and Checking It Twice
- Blog
01.10.2019
2019: What to Expect in Employee Health & Benefits
- Blog
01.16.2019
Understanding the Changes to Minnesota’s Whistleblower Act
- Event
02.19.2019
Seminar | Navigating FMLA/ADA in Personal Health & Workers Compensation